Management of fetuses with apparent normal growth and abnormal cerebroplacental ratio: A risk-based approach near term

Data de publicació: Data Ahead of Print:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Khalil, Asma

Grups d'Investigació

Abstract

Introduction: Cerebroplacental ratio (CPR) has been shown to be an independent predictor of adverse perinatal outcome at term and a marker of failure to reach the growth potential (FRGP) regardless of fetal size, being abnormal in compromised fetuses with birthweight above the 10th centile. The main aim of this study was to propose a risk-based approach for the management of pregnancies with normal estimated fetal weight (EFW) and abnormal CPR near term.Material and methods: This was a retrospective study of 943 pregnancies, that underwent an ultrasound evaluation of EFW and CPR at or beyond 34 weeks. CPR values were converted into multiples of the median (MoM) and EFW into centiles according to local references. Pregnancies were then divided into four groups: normal fetuses (defined as EFW >= 10th centile and CPR >= 0.6765 MoM), small for gestational age (EFW <10th centile and CPR >= 0.6765 MoM), fetal growth restriction (EFW <10th centile and CPR <0.6765 MoM), and fetuses with apparent normal growth (EFW >= 10th centile) and abnormal CPR (<0.6765 MoM), that present FRGP. Intrapartum fetal compromise (IFC) was defined as an abnormal intrapartum cardiotocogram or pH requiring cesarean delivery. Risk comparisons were performed among the four groups, based on the different frequencies of IFC. The risks of IFC were subsequently extrapolated into a gestational age scale, defining the optimal gestation to plan the birth for each of the four groups.Results: Fetal growth restriction was the group with the highest frequency of IFC followed by FRGP, small for gestational age, and normal groups. The "a priori" risks of the fetal growth restriction and normal groups were used to determine the limits of two scales. One defining the IFC risk and the other defining the appropriate gestational age for delivery. Extrapolation of the risk between both scales placed the optimal gestational age for delivery at 39 weeks of gestation in the case of FRGP and at 40 weeks in the case of small for gestational age.Conclusions: Fetuses near term may be evaluated according to the CPR and EFW defining four groups that present a progressive risk of IFC. Fetuses in pregnancies complicated by FRGP are likely to benefit from being delivered at 39 weeks of gestation.

© 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

Dades de la publicació

ISSN/ISSNe:
0001-6349, 1600-0412

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA  Wiley-Blackwell

Tipus:
Article
Pàgines:
334-341
PubMed:
38050342
Factor d'Impacte:
1,232 SCImago
Quartil:
Q1 SCImago

Documents

  • No hi ha documents

Mètriques

Filiacions

Filiacions no disponibles

Keywords

  • adverse perinatal outcome, cerebroplacental ratio, ductus venosus Doppler, failure to reach growth potential, fetal Doppler, fetal growth restriction, middle cerebral artery Doppler, small baby, small for gestational age, umbilical artery doppler

Campos d'Estudi

Projectes associats

UTILIDAD DEL TRATAMIENTO TOCOLITICO DE MANTENIMIENTO EN EL MANEJO DE LA AMENAZA DE PARTO PREMATURO (APP)

Investigador Principal: MÁXIMO VENTO TORRES

EC11-246 . 2012

RED DE SALUD MATERNO INFANTIL Y DEL DESARROLLO

Investigador Principal: MÁXIMO VENTO TORRES

RD12/0026/0012 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

PAPEL DEL FACTOR DE CRECIMIENTO PLACENTARIO EN EL MANEJO DE LA PREECLAMPSIA NO SEVERA: ESTUDIO ALEATORIZADO

Investigador Principal: ALFREDO JOSÉ PERALES MARÍN

PI15/01935 . INSTITUTO DE SALUD CARLOS III . 2016

Iplacenta. innovation in pacenta modelling for maternal and fetal health.

Investigador Principal: JOSÉ MORALES ROSELLÓ

765274 . COMISION EUROPEA . 2018

ENSAYO MULTICÉNTRICO, ABIERTO, ALEATORIZADO, DE DOSIS ÚNICA, CONTROLADO, DE XOMA 213 ADMINISTRADO POR VÍA INTRAVENOSA A MUJERES DESPUÉS DEL PARTO PARA LA SUPRESIÓN DE LA LACTANCIA.

Investigador Principal: ALFREDO JOSÉ PERALES MARÍN

X213220

ENSAYO EN FASE III, ALEATORIZADO, DOBLE CIEGO O CON ENMASCARAMIENTO PARA EL OBSERVADOR, CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UNA VACUNA DE SUBUNIDAD F PREFUSIÓN CONTRA EL VIRUS RESPIRATORIO SINCITIAL (VRS) EN LACTANTES NACIDOS D E MUJERES VACUNADAS DURANTE EL EMBARAZO

Investigador Principal: EMILIO MONTEAGUDO MONTESINOS

C3671008 . 2020

ESTUDIO FASE 2/3 CONTROLADO CON PLACEBO, ALEATORIZADO, CEGADO PARA EL OBSERVADOR, PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD Y LA INMUNOGENICIDAD DE UNA VACUNA CANDIDATA DE ARN (BNT162B2) DEL SARS-COV-2, CONTRA COVID-19 EN MUJERES EMBARAZADAS SANAS DE 18 AÑOS DE EDAD Y MAYORES.

Investigador Principal: VICENTE JOSE DIAGO ALMELA

C4591015 . 2021

EVALUACIÓN DE LA EFICACIA DEL USO DE CLORHEXIDINA DURANTE EL PRIMER TRIMESTRE COMO REGULADOR DE LA MICROBIOTA VAGINAL EN LA REDUCCIÓN DE PARTO PREMATURO.

Investigador Principal: JOSÉ MORALES ROSELLÓ

PLUVA . 2021

Comparison of maternal-fetal outcomes among unvaccinated and vaccinated pregnant women with Covid-19.

Investigador Principal: ALICIA MARTÍNEZ VAREA

CoVaGest . 2022

Elaboración de un algoritmo de predicción de parto tras inducción basado en criterios clínicos, epidemiológicos y ecográficos.

Investigador Principal: JOSÉ MORALES ROSELLÓ

Prepain . 2023

Compartir la publicació